Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin and Dapagliflozin Add-On to Metformin in Type 2 Diabetes
NCT01606007Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2012
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + Metformin, Dapagliflozin + Metformin and Saxagliptin + Dapagliflozin + Metformin (3 arms). Primary endpoint: Adjusted Mean Change From Baseline in Hemoglobin A1C at 24 weeks. Started Jul 2012; status: completed.
02
Drugs
saxagliptindapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01606007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01606007.